NO169711C - Analogifremgangsmaate ved fremstilling av terapeutisk aktive etylendiaminmonoamid-derivater - Google Patents

Analogifremgangsmaate ved fremstilling av terapeutisk aktive etylendiaminmonoamid-derivater

Info

Publication number
NO169711C
NO169711C NO853390A NO853390A NO169711C NO 169711 C NO169711 C NO 169711C NO 853390 A NO853390 A NO 853390A NO 853390 A NO853390 A NO 853390A NO 169711 C NO169711 C NO 169711C
Authority
NO
Norway
Prior art keywords
ethylendiamine
preparation
therapeutically active
analogy procedure
monoamide derivatives
Prior art date
Application number
NO853390A
Other languages
English (en)
Norwegian (no)
Other versions
NO853390L (no
NO169711B (no
Inventor
Rene Imhof
Emilio Kyburz
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CH4132/84A external-priority patent/CH661043A5/de
Priority claimed from CH2404/85A external-priority patent/CH664755A5/de
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO853390L publication Critical patent/NO853390L/no
Publication of NO169711B publication Critical patent/NO169711B/no
Publication of NO169711C publication Critical patent/NO169711C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrrole Compounds (AREA)
NO853390A 1984-08-29 1985-08-28 Analogifremgangsmaate ved fremstilling av terapeutisk aktive etylendiaminmonoamid-derivater NO169711C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH4132/84A CH661043A5 (en) 1984-08-29 1984-08-29 Ethylenediamine monoamide derivatives
CH2404/85A CH664755A5 (de) 1985-06-05 1985-06-05 Aethylendiaminmonoamid-derivat.

Publications (3)

Publication Number Publication Date
NO853390L NO853390L (no) 1986-03-03
NO169711B NO169711B (no) 1992-04-21
NO169711C true NO169711C (no) 1992-07-29

Family

ID=25690366

Family Applications (1)

Application Number Title Priority Date Filing Date
NO853390A NO169711C (no) 1984-08-29 1985-08-28 Analogifremgangsmaate ved fremstilling av terapeutisk aktive etylendiaminmonoamid-derivater

Country Status (28)

Country Link
US (1) US4764522A (sv)
JP (2) JPH0764817B2 (sv)
KR (1) KR920007269B1 (sv)
AR (1) AR244209A1 (sv)
AT (1) AT391694B (sv)
AU (1) AU582381B2 (sv)
BE (1) BE903110A (sv)
BG (1) BG60401B1 (sv)
CA (1) CA1261335A (sv)
DE (1) DE3530046C2 (sv)
DK (1) DK162888C (sv)
ES (2) ES8705372A1 (sv)
FI (1) FI83511C (sv)
FR (1) FR2569694B1 (sv)
GB (1) GB2163746B (sv)
GR (1) GR852071B (sv)
HU (1) HU197309B (sv)
IE (1) IE58788B1 (sv)
IL (1) IL76176A (sv)
IT (1) IT1190385B (sv)
LU (1) LU86049A1 (sv)
MC (1) MC1696A1 (sv)
NL (1) NL193583C (sv)
NO (1) NO169711C (sv)
NZ (1) NZ213193A (sv)
PH (1) PH22813A (sv)
PT (1) PT81041B (sv)
SE (1) SE464083B (sv)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0352581A3 (de) * 1988-07-28 1990-07-04 F. Hoffmann-La Roche Ag Aethylendiaminmonoamid-Derivate
US5204482A (en) * 1988-07-28 1993-04-20 Hoffman-Laroche Inc. Compounds for treating and preventing cognitive diseases and depression and methods of making same
CA2245055C (en) * 1989-02-28 2003-03-25 F. Hoffmann-La Roche Ag Amidation of pyridines
EP0451790A1 (de) * 1990-04-12 1991-10-16 Hoechst Aktiengesellschaft 3,5-disubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu deren Herstellung, diese enthaltende Mittel und ihre Verwendung
JPH04295470A (ja) * 1991-03-22 1992-10-20 Wakamoto Pharmaceut Co Ltd モノアミンオキシダーゼ−ｂ酵素阻害活性を有する１，２，４−オキサジアゾール誘導体及びその製造法
UA39849C2 (uk) * 1991-03-26 2001-07-16 Ф.Хоффманн-Ля Рош Аг ПОХІДНІ N-АЦИЛ-<font face="Symbol">a</font>-АМІНОКИСЛОТИ АБО ЇХ ФІЗІОЛОГІЧНО ПРИЙНЯТНІ СОЛІ, ПРОСТІ АБО СКЛАДНІ ЕФІРИ, АМІДИ АБО ЇХ ГІДРАТИ ЯК ФАРМАЦЕВТИЧНО АКТИВНІ РЕЧОВИНИ
US5545658A (en) * 1991-03-26 1996-08-13 Hoffman-La Roche Inc. Amino acid derivatives
FR2803592A1 (fr) * 2000-01-06 2001-07-13 Aventis Cropscience Sa Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant.
ES2414706T3 (es) * 2001-12-06 2013-07-22 Fibrogen, Inc. Métodos para aumentar la eritropoyetina endógena
US6667327B2 (en) * 2002-02-04 2003-12-23 Hoffmann-La Roche Inc. Pyridine amido derivatives
DE602004017206D1 (de) * 2003-10-23 2008-11-27 Hoffmann La Roche Benzazepin-derivate als mao-b-hemmer
US8138209B2 (en) * 2005-07-13 2012-03-20 Jenrin Discovery, Inc. Substituted picolinamides as MAO-B inhibitors useful for treating obesity
WO2008010794A1 (en) * 2006-07-18 2008-01-24 Renaissance Medicine, Llc Pharmaceutical preparations of crystalline lazabemide
WO2008010796A1 (en) * 2006-07-18 2008-01-24 Renaissance Medicine, Llc Process for preparing pyridine-2-carboxamides and intermediates therefor
FR2904317A1 (fr) * 2006-07-27 2008-02-01 Inst Nat Sante Rech Med Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques
EP2085390A1 (en) * 2008-01-31 2009-08-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors
WO2011028740A1 (en) * 2009-09-03 2011-03-10 Glaxo Group Limited ENaC BLOCKERS
CN114404414A (zh) 2013-06-13 2022-04-29 阿克比治疗有限公司 用于治疗贫血症的组合物和方法
BR112017021097B1 (pt) 2015-04-01 2024-01-02 Akebia Therapeutics, Inc Formulação de dosagem oral e seu uso
WO2019028150A1 (en) 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB451304A (en) * 1934-07-07 1936-08-04 Karl Merck Process for the manufacture of new derivatives of pyrazinemonocarboxylic acid
DE1217385B (de) * 1962-11-09 1966-05-26 J. R. Geigy A.-G., Basel (Schweiz) Verfahren zur Herstellung von neuen Picolinsäurederivafen
NL6707566A (sv) * 1966-08-17 1968-02-19
US4041032A (en) * 1974-01-16 1977-08-09 Yamanouchi Pharmaceutical Co., Ltd. Pyrazine derivatives
GB1521471A (en) * 1974-06-05 1978-08-16 Randall & Son Ltd J Token-deposit locks
GB1509300A (en) * 1975-12-05 1978-05-04 Ici Ltd Ethanolamine derivatives
DE3239573A1 (de) * 1981-10-28 1983-05-19 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Substituierte picolinsaeuren, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende arzneimittel
IE54220B1 (en) * 1981-12-23 1989-07-19 Ici Plc Phenol esters
CH653670A5 (de) * 1983-03-03 1986-01-15 Hoffmann La Roche Benzamid-derivate.

Also Published As

Publication number Publication date
IL76176A0 (en) 1985-12-31
PT81041A (en) 1985-09-01
MC1696A1 (fr) 1986-07-18
DK162888B (da) 1991-12-23
ES8705372A1 (es) 1987-05-01
IE852118L (en) 1986-02-28
HU197309B (en) 1989-03-28
DE3530046A1 (de) 1986-03-13
GB8521358D0 (en) 1985-10-02
SE464083B (sv) 1991-03-04
NO853390L (no) 1986-03-03
US4764522A (en) 1988-08-16
GB2163746B (en) 1988-06-22
AT391694B (de) 1990-11-12
GB2163746A (en) 1986-03-05
AR244209A1 (es) 1993-10-29
ES546482A0 (es) 1987-05-01
AU4663685A (en) 1986-03-06
CA1261335A (en) 1989-09-26
NO169711B (no) 1992-04-21
IT1190385B (it) 1988-02-16
NL8502374A (nl) 1986-03-17
JPH0764817B2 (ja) 1995-07-12
PH22813A (en) 1988-12-27
BG96645A (bg) 1993-12-24
ES552399A0 (es) 1987-11-01
FI83511C (sv) 1991-07-25
KR920007269B1 (ko) 1992-08-29
IT8521865A0 (it) 1985-08-05
PT81041B (pt) 1988-01-22
GR852071B (sv) 1985-12-24
LU86049A1 (de) 1986-09-11
BE903110A (fr) 1986-02-24
HUT38317A (en) 1986-05-28
DK162888C (da) 1992-05-11
FI83511B (fi) 1991-04-15
AU582381B2 (en) 1989-03-23
NZ213193A (en) 1989-10-27
KR870002078A (ko) 1987-03-30
FR2569694B1 (fr) 1991-05-03
IE58788B1 (en) 1993-11-17
JPH07300417A (ja) 1995-11-14
IL76176A (en) 1989-02-28
FR2569694A1 (fr) 1986-03-07
JPH0825879B2 (ja) 1996-03-13
FI853140L (fi) 1986-03-01
JPS6160657A (ja) 1986-03-28
SE8504014L (sv) 1986-03-01
FI853140A0 (fi) 1985-08-15
ES8800158A1 (es) 1987-11-01
DK391485A (da) 1986-03-01
NL193583B (nl) 1999-11-01
BG60401B1 (en) 1995-02-28
NL193583C (nl) 2000-03-02
DE3530046C2 (de) 1997-12-04
ATA251585A (de) 1990-05-15
SE8504014D0 (sv) 1985-08-28
DK391485D0 (da) 1985-08-28

Similar Documents

Publication Publication Date Title
NO172540C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive pyrrolderivater
NO169711C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive etylendiaminmonoamid-derivater
NO159089C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive glutarimidderivater.
NO170483C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive tetrahydronaftalin- og indanderivater
NO852699L (no) Fremgangsmaate ved fremstilling av terapeutisk anvendelige substituerte benzoatesterderivater av 3-hydroxymorfinaner
NO174101C (no) Analogifremgangsmåte ved fremstilling av terapeutisk aktive triazolderivater
NO844879L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive indolderivater
NO173544C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 2- tiometyl-substituerte 1,4-dihydropyridiner
NO151588C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive n2-arylsulfonyl-l-argininamid-derivater
NO170884C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive pyrimidinderivater
NO810762L (no) Fremgangsmaate for fremstilling av farmakologisk aktive heterocykliske forbindelser
NO851695L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 2-(n-substituert-guanidino)-4-heteroaryl-tiazol-derivater
NO176275C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive pyridazinonderivater
NO166083C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive pyridazodiazepinderivater.
NO167569C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme benzimidazolderivater.
NO168355C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater
NO165841C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive heteroaryl-3-okso-propannitril-derivater.
NO165842C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive cefem-forbindelser.
NO157538C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive benzothiazolsufonamidderivater.
NO164020C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive fenetanolaminderivater.
NO171065C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive pyrimidinderivater
NO167923C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive peptidsubstituerte heterocykliske forbindelser
NO163330C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive isokinolinderivater.
NO161313C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive fluorallylaminderivater.
NO158673C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive azurenderivater.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees